A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia

Journal of Urology

Volumn 192, Issue 1, 2014, Pages 150-156

  McVary, Kevin T ^a   Roehrborn, Claus G ^b   Chartier Kastler, Emmanuel ^c   Efros, Mitchell ^d   Bugarin, Denise ^e   Chen, Ru ^e   Patel, Anand ^e   Haag Molkenteller, Cornelia ^e  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SORBONNE UNIVERSITÉ   (France)

^d Accumed Research Inc Garden City New York Accumed Research Inc   (United States)

^e ALLERGAN INC   (United States)

Author keywords

benign prostatic hyperplasia; lower urinary tract symptoms; onabotulinumtoxinA; prostate; prostatic hyperplasia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; ACETYLCHOLINE RELEASE INHIBITOR;

ABDOMINAL PAIN; ACUTE GASTROENTERITIS; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; HEMATURIA; HEMOSPERMIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; KIDNEY CYST; LOWER URINARY TRACT SYMPTOM; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PLACEBO EFFECT; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHAM PROCEDURE; SINGLE BLIND PROCEDURE; URINE FLOW RATE; DIGITAL RECTAL EXAMINATION; DRUG SAFETY; URINALYSIS; CLINICAL TRIAL; COMPLICATION; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED; VERY ELDERLY;

ACETYLCHOLINE RELEASE INHIBITORS; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA;

EID: 84902546394     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.02.004     Document Type: Article

References (15)

1. G. Maria, G. Brisinda, and I.M. Civello et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study Urology 62 2003 259
2. Y.C. Chuang, P.H. Chiang, and C.C. Huang et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates Urology 66 2005 775
3. Y.C. Chuang, P.H. Chiang, and N. Yoshimura et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia BJU Int 98 2006 1033
4. G. Brisinda, F. Cadeddu, and S. Vanella et al. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results Urology 73 2009 90
5. E.D. Crawford, K. Hirst, and J.W. Kusek et al. Effects of 100 and 300 Units of onabotulinumtoxinA on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial J Urol 186 2011 965
6. C. Marchal, J.E. Perez, and B. Herrera et al. The use of botulinum toxin in benign prostatic hyperplasia Neurourol Urodyn 31 2012 86
7. A. Oeconomou, H. Madersbacher, and G. Kiss et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature Eur Urol 54 2008 765
8. M. Marberger, E. Chartier-Kastler, and B. Egerdie et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia Eur Urol 63 2013 496
9. T. Yokoyama, Y. Yamamoto, and T. Suzuki et al. Intraprostatic botulinum neurotoxin type A injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin Acta Med Okayama 66 2012 291
10. M. Nikoobakht, A. Daneshpajooh, and H. Ahmadi et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: initial experience with Dysport Scand J Urol Nephrol 44 2010 151
11. M.B. Chancellor, C.J. Fowler, and A. Apostolidis et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract Nat Clin Pract Urol 5 2008 319
12. R. Takahashi, T. Yunoki, and S. Naito et al. Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats J Urol 188 2012 1993
13. J. Silva, R. Pinto, and T. Carvalho et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function BJU Int 107 2011 1950
14. E. Sacco, R. Bientinesi, and F. Marangi et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic onabotulinumtoxinA: 3-month results of a prospective single-armed cohort study BJU Int 110 2012 E837
15. H. Lepor, D. Sypherd, and G. Machi et al. Randomized double-blind study comparing the effectiveness of balloon dilation of the prostate and cystoscopy for the treatment of symptomatic benign prostatic hyperplasia J Urol 147 1992 639